BRAF and thyroid cancer: With regard to the thyroid cancer cells that carried a wild-type BRAF gene yet still could not be reprogrammed (C643 and Hth74), an entirely different blocking pathway is clearly operative—suggesting, importantly, that the old categorization scheme for designating ATCs based on histopathological characteristics may actually need to be updated, refined, and rendered more discrete based, at least in part, on the functional and molecular attributes unveiled by the reprogram enablement assay.